CPQA Laboratory Presents work at the 2024 ASMS Annual Conference
August 23, 2024
Researchers from the CPQA laboratory at the University at Buffalo presented three abstracts at the 2024 American Society for Mass Spectrometry Annual Conference in Anaheim, California.
“Developing Global Access to Mass Spectrometry through Research Capacity Building Programs” discusses the difficulty of conducting mentored research in clinical pharmacology and therapeutics in low and middle-income countries and CPQA’s efforts to build a training program at Mass Spectrometry Cores and Translational Pharmacology Laboratory Cores as well as establishing a globalization strategy for developing other mass spectrometry cores in low and middle-income countries. This presentation highlights the importance of global training initiates around the world.
“Development of an LC-MS/MS Method for Quantifying PGT 121.414.LS in Human Serum” presents findings on the advantages of liquid chromatography-tandem mass spectrometry (LC-MS/MS) over traditional ligand-binding assays for quantifying the broadly neutralizing antibody (bNab) PGT 121.414.LS in human serum for pharmacokinetic studies.
“Development of an LC-MS/MS Method for the Determination of Morphine, Oxycodone, and Hydrocodone in Human Plasma” reviews the increasing need to monitor and quantitate the concentration of opioids in patients to determine appropriate therapeutic ranges, drug interactions, and dosing in special populations as well as the creation of a simple and robust LC-MS/MS method for a more unified detection protocol of opioids in human plasma where there was no established protocol previously.
